Basic research in pulmonology

Archivos de Bronconeumologia

Volumn 44, Issue 11, 2008, Pages 621-628

  Gea, Joaquim ^a,b,c  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL DEL MAR   (Spain)

Author keywords

Basic research; Experimental models; Molecular biology; Respiratory diseases

Indexed keywords

BCG VACCINE; BIOLOGICAL MARKER; GELATINASE B; IMMUNOGLOBULIN E; INTERLEUKIN 8; OMALIZUMAB; RUTI VACCINE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ASTHMA; BLOOD CULTURE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG COST; GENE THERAPY; HEALTH CARE COST; HUMAN; LUNG CANCER; LUNG DISEASE; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG TRANSPLANTATION; LUNG TUBERCULOSIS; MEDICAL RESEARCH; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; REPERFUSION INJURY; RESPIRATORY TRACT INFECTION; REVIEW; SLEEP APNEA SYNDROME; SPUTUM CULTURE; BIBLIOMETRICS; LUNG TUMOR; PUBLICATION; PULMONOLOGY; RESEARCH; SLEEP DISORDER; STATISTICS;

BIBLIOMETRICS; HUMANS; LUNG NEOPLASMS; LUNG TRANSPLANTATION; PERIODICALS AS TOPIC; PULMONARY FIBROSIS; PULMONARY MEDICINE; REPERFUSION INJURY; RESEARCH; RESPIRATORY TRACT INFECTIONS; SLEEP DISORDERS, INTRINSIC;

EID: 55949112502     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S1579-2129(08)60116-0     Document Type: Article

References (82)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO working meeting. Available from: www.goldcopd.com
2. Celli BR, MacNee W, and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-46.
3. American Thoracic Society. Skeletal muscle dysfunction in chronic obstructive pulmonary disease: a statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med. 1999;159:S1-S40.
4. Swallow E, Reyes D, Hopkinson N, Man W, Porcher R, Cetti E, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax. 2007;62:115-20.
5. Gea J, Barreiro E, Orozco-Levi M. Skeletal muscle adaptation to disease states. In: Bottinelli R, Reggiani C, editors. Skeletal muscle plasticity in health and disease: from genes to whole muscle. Doordrecht: Springer; 2006. p. 315-60.
6. Morlà M, Iglesias A, Sauleda J, Cosio B, Agustí A, Busquets X. Disminución de la expresión de la bomba de calcio sarcoplásmica (SERCA2) en el músculo esquelético de pacientes con EPOC y bajo peso corporal. Arch Bronconeumol. 2007;43:4-8.
7. Gea J, Barreiro E, Orozco-Levi M. Free radicals, cytokines and respiratory muscles in COPD patients. Clin Pulm Med. 2007;14:117-26.
8. Izquierdo JL, Almonacid C, Parra T, Pérez J. Inflamación pulmonar y sistémica en 2 fenotipos de EPOC. Arch Bronconeumol. 2006;42:332-7.
9. Peces-Barba G, Barberà JA, Agustí A, Casanova C, Casas A, Izquierdo JL, et al. Diagnóstico y manejo de la enfermedad pulmonar obstructiva crónica: guía conjunta de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y la Sociedad Latinoamericana del Tórax (ALAT). Arch Bronconeumol. 2008;44:271-81.
10. Avilés B, Belda J, Margarit G, Bellido-Casado J, Martínez-Bru C, Casán P. Marcadores de remodelado bronquial en el esputo inducido de fumadores sanos. Arch Bronconeumol. 2006;42:235-40.
11. Margarit G, Belda J, Casan P, Sanchis J. Método para amplificar cultivos primarios de células epiteliales bronquiales. Arch Bronconeumol. 2005;41:524-7.
12. Belda J, Margarit G, Martínez C, Casan P, Rodríguez-Jerez F, Brufal M, et al. Exudado bronquial de proteínas séricas en las crisis de asma. Arch Bronconeumol. 2005;41:328-33.
13. Atkinson JJ, Señor RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol. 2003;28:12-24.
14. Vignola AM, Riccobono L, Mirabella A, Profita M, Chánez P, Bellia V, et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med. 1998;158:1945-50.
15. Cabrera-Navarro P, Rodríguez-Gallego JC. Perfil farmacológico de omalizumab. Arch Bronconeumol. 2006;42 Suppl 1:26-31.
16. Cabrera-Navarro P. Antiinmunoglobulina E, un anticuerpo monoclonal, en el tratamiento de las enfermedades respiratorias. Arch Bronconeumol. 2006;42:241-5.
17. Cabrera-Navarro P. Uso terapéutico de los anticuerpos monoclonales en neumología. Arch Bronconeumol. 2006;42 Suppl 2:2-11.
18. Easthope S, Jarvis V. Omalizulab. Drugs. 2001;61:253-60.
19. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fce epsilon RI expression and function. J Allergy Clin Immunol. 2004;114:527-30.
20. Djukanoviç R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170:583-93.
21. Ramos-Barbón D. Investigación básica sobre asma: ¿hacia dónde nos dirigimos? Arch Bronconeumol. 2006;42:613-5.
22. Ramos-Barbón D. ¿Podemos modificar el remodelado bronquial en el asma? Arch Bronconeumol. 2005;41 Suppl 5:3-9.
23. Cortijo J. Modelos experimentales de asma. Aportaciones y limitaciones. Arch Bronconeumol. 2003;39:54-6.
24. Boyle P, Gandini S, Gray N. Epidemiology of lung cancer: a century of great success and ignominious failure. In: Hansen HH, editor. Textbook of lung cancer. London: Martin Dunitz Ltd.; 2000: p. 13-25.
25. Dubey S, Powell CA. Update in lung cancer 2007. Am J Respir Crit Care Med. 2008;177:941-6.
26. Beck WT, Dalton WS. Mechanisms of drug resistance. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 6th ed. Philadelphia: JB Lippincott Company; 2001. p. 498-512.
27. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92:1295-302.
28. Paredes A, Blanco C, Echenique M, Lobo C. Expresión de proteínas relacionadas con resistencia a múltiples fármacos y resistencia a la quimioterapia en el cáncer de pulmón. Arch Bronconeumol. 2007;43:479-84.
29. Rodrigo-Garzón M, Tirapu I, Arina A, Centelles MN, Zulueta J. Aplicación de tratamiento génico a un modelo subcutáneo de cáncer de pulmón murino. Arch Bronconeumol. 2006;42:526-32.
30. Seijo LM, Bastarrika G, Lozano MD, Zulueta JJ. Experiencia preliminar en el uso de la navegación electromagnética para el diagnóstico de nódulos pulmonares periféricos y adenopatías mediastínicas. Arch Bronconeumol. 2007;43:460-3.
31. Seijo L, Campo A, Alcaide AB, Lacunza MM, Armendáriz AC, Zulueta JJ. Manejo ambulatorio del derrame pleural maligno mediante colocación de un catéter de drenaje tunelizado. Experiencia preliminar. Arch Bronconeumol. 2006;42:660-2.
32. Galagudza MM, Blokhin IO, Shmonin AA, Mischenko KA. Reduction of myocardial ischemia-reperfusion injury with pre- and postconditioning: molecular mechanisms and therapeutic targets. Cardiovasc Hematol Disord Drug Targets. 2008;8:47-65.
33. Castellanos M, Sobrino T, Castillo J. Evolving paradigms for neuroprotection: molecular identification of ischemic penumbra. Cerebrovasc Dis. 2006;21 Suppl 2:71-9.
34. Ovechkin AV, Lominadze D, Sedoris KC, Robinson TW, Tyagi SC, Roberts AM. Lung ischemia-reperfusion injury: implications of oxidative stress and platelet-arteriolar wall interactions. Arch Physiol Biochem. 2007;113:1-12.
35. Thabut G, Mal H, Cerrina J, Dartevelle P, Dromer C, Velly JF, et al. Graft ischemic time and outcome of lung transplantation: a multicenter analysis. Am J Respir Crit Care Med. 2005;171:786-91.
36. Novick RJ, Bennett LE, Meyer DM, Hosenpud JD. Influence of graft ischemic time and donor age on survival after lung transplantation. J Heart Lung Transplant. 1999;18:425-31.
37. Santana-Rodríguez N, Martín JL, Ponce MA, López A, Ruiz JA, Torres A, et al. Valoración de la lesión de isquemia-reperfusión y del rechazo agudo precoz en el trasplante pulmonar experimental con tiempo de isquemia prolongado. Arch Bronconeumol. 2007;43:373-7.
38. Matilla JM, García M, Sánchez M, Gayoso MJ, Heras F, Jiménez M, et al. Estudio de la expresión de interleucina-8 en el tejido pulmonar durante la isquemia-reperfusión. Arch Bronconeumol. 2007;43:542-8.
39. Mal H, Dehoux M, Sleiman C, Boczkowski J, Lesèche G, Pariente R, et al. Early release of proinflammatory cytokines after lung transplantation. Chest. 1998;113:645-51.
40. Schröder JM, Mrowietz U, Christophers E. Purification and partial biologic characterization of a human lymphocyte-derived peptide with potent neutrophil-stimulating activity. J Immunol. 1988;140:3534-40.
41. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002;165:277-304.
42. Xaubet A, Ancochea J, Blanquer R, Montero C, Morell F, Rodríguez Becerra E, et al; Grupo de Investigación en EnfermedadesPulmonares Intersticiales Difusas. Área de Técnicas y Trasplante. SEPAR. Diagnóstico y tratamiento de las enfermedades pulmonares intersticiales difusas. Arch Bronconeumol. 2003;39:580-600.
43. Serrano M, Molina-Molina M, Ramírez J, Sánchez M, Xaubet A. Fibrosis pulmonar intersticial centrada en las vías aéreas asociada a la inhalación de productos de limpieza. Arch Bronconeumol. 2006;42:557-9.
44. Serrano-Mollar A, Nacher M, Gay-Jordi G, Closa D, Xaubet A, Bulbena O. Intratracheal transplantation of alveolar type II cells reverses bleomycin-induced lung fibrosis. Am J Respir Crit Care Med. 2007;176:1261-8.
45. Acosta O. Marcadores séricos en la fibrosis pulmonar idiopática. Implicación pronóstica. Arch Bronconeumol. 2006;42:377-9.
46. Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M, Inoue Y, et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis. 1993;148:637-42.
47. Winkler MK, Fowlkes JL. Metalloproteinase and growth factor interactions: do they play a role in pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol. 2002;283:L1-L11.
48. Suga M, Iyonaga K, Ichiyasu H, Saita N, Yamasaki H, Ando M. Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. Eur Respir J. 1999;14:376-82.
49. Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000;162:1109-14.
50. Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002;165:378-81.
51. Nakayama M, Satoh H, Ishikawa H, Fujiwara M, Kamma H, Ohtsuka M, et al. Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases. Chest. 2003;123:2001-6.
52. Sime PJ, Marr RA, Gauldie D, Xing Z, Hewlett BR, Graham FL, et al. Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. Am J Pathol. 1998;153:825-32.
53. Xaubet A, Marín-Arguedas A, Lario S, Ancochea J, Morell F, Ruiz-Manzano J, et al. Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168: 431-5.
54. Yong SJ, Adlakha A, Limper AH. Circulating transforming growth factor-beta(1): a potential marker of disease activity during idiopathic pulmonary fibrosis. Chest. 2001;120 1 Suppl:68-70.
55. Molina-Molina M, Lario S, Luburich P, Ramírez J, Carrión MT, Xaubet A. Determinación en plasma del factor transformador del crecimiento b1 en la fibrosis pulmonar idiopática. Arch Bronconeumol. 2006;42:380-3.
56. Molina-Molina M, Pereda J, Xaubet A. Modelos experimentales para el estudio de la fibrosis pulmonar: utilidad práctica actual y futura. Arch Bronconeumol. 2007;43:501-7.
57. Phan SH, Thrall RS, Ward PA. Bleomycin-induced pulmonary fibrosis in rats: biochemical demonstration of increased rate of collagen synthesis. Am Rev Respir Dis. 1980;121:501-6.
58. Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol. 2005;33:9-13.
59. Antonini JM, Starks K, Roberts JR, Millecchia L, Yang HM, Rao KM. Changes in F-actin organization induced by hard metal particle exposure in rat pulmonary epithelial cells using laser scanning confocal microscopy. In Vitr Mol Toxicol. 2000;13:5-16.
60. Li X, Zhang H, Soledad-Conrad V, Zhuang J, Uhal BD. Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. Am J Physiol Lung Cell Mol Physiol. 2003;284:L501-L7.
61. Molina-Molina M, Serrano-Mollar A, Bulbena O, Fernández-Zabalegui L, Closa D, Marín-Arguedas A, et al. Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis. Thorax. 2006;61:604-10.
62. Haston CK, Wang M, Dejournett RE, Zhou X, Ni D, Gu X, et al. Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice. Hum Mol Genet. 2002; 11:1855-63.
63. Card JW, Racz WJ, Brien JF, Margolin SB, Massey TE. Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. Toxicol Sci. 2003;75:169-80.
64. Coin PG, Osornio-Vargas AR, Roggli VL, Brody AR. Pulmonary fibrogenesis after three consecutive inhalation exposures to chrysotile asbestos. Am J Respir Crit Care Med. 1996;154:1511-9.
65. Arras M, Louahed J, Simoen V, Barbarin V, Misson P, Van den Brûle S, et al. B lymphocytes are critical for lung fibrosis control and prostaglandin E2 regulation in IL-9 transgenic mice. Am J Respir Cell Mol Biol. 2006;34:573-80.
66. Portnoy J, Pan T, Dinarello CA, Shannon JM, Westcott JY, Zhang L, et al. Alveolar type II cells inhibit fibroblast proliferation: role of IL1alpha. Am J Physiol Lung Cell Mol Physiol. 2006;290: L307-L16.
67. Gea J, Barreiro E. Actualización en los mecanismos de disfunción muscular en la EPOC. Arch Bronconeumol. 2008;44:328-37.
68. Kontogianni K, Messini-Nikolaki N, Christou K, Gourgoulianis K, Tsilimigaki S, Piperakis SM. DNA damage and repair capacity in lymphocytes from obstructive sleep apnea patients. Environ Mol Mutagen. 2007;48:722-7.
69. Hernández C, Abreu J, Abreu P, Colino R, Jiménez A. Efectos del tratamiento con CPAP nasal en el estrés oxidativo en pacientes con síndrome de apnea del sueño. Arch Bronconeumol. 2006;42:125-9.
70. Christou K, Moulas AN, Pastaka C, Gourgoulianis KI. Antioxidant capacity in obstructive sleep apnea patients. Sleep Med. 2003;4:225-8.
71. Christou K, Kostikas K, Pastaka C, Tanou K, Antoniadou I, Gourgoulianis KI. Nasal continuous positive airway pressure treatment reduces systemic oxidative stress in patients with severe obstructive sleep apnea syndrome. Sleep Med. In press.
72. Barreiro E, Nowinski A, Gea J, Sliwinski P. Oxidative stress in the external intercostal muscles of patients with obstructive sleep apnoea. Thorax. 2007;62:1095-101.
73. World Health Organization. Global tuberculosis control: surveillance, planning, financing. Geneva: WHO Report; 2004.
74. Cardona PJ, Amat I. Origen y desarrollo de RUTI, una nueva vacuna terapéutica contra la infección por Mycobacterium tuberculosis. Arch Bronconeumol. 2006;42:25-32.
75. Cardona PJ, Julián E, Vallès X, Gordillo S, Muñoz M, Luquin M, et al. Production of antibodies against glycolipids from the Mycobacterium tuberculosis cell wall in aerosol murine models of tuberculosis. Scand J Immunol. 2002;55:639-45.
76. Cardona PJ. Vacunas terapéuticas contra la tuberculosis: un futuro brillante. Arch Bronconeumol. 2007;43:591-3.
77. Cardona PJ, Amat I, Gordillo S, Arcos V, Guirado E, Díaz J, et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine. 2005; 23:1393-8.
78. Molinos L. Detección de antígenos en orina. Arch Bronconeumol. 2006;42:101-3.
79. Marcos MA, Jiménez de Anta MT, de la Bellacasa JP, González J, Martínez E, García E, et al. Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults. Eur Respir J. 2003;21:209-14.
80. Guerrero C, Toldos CM, Yagüe G, Ramírez C, Rodríguez T, Segovia M. Comparison of diagnostic sensitivities of three assays (Bartels enzyme immunoassay [EIA], Biotest EIA, and Binax NOW immunochromatographic test) for detection of Legionella pneumophila serogroup 1 antigen in urine. J Clin Microbiol. 2004; 42:467-8.
81. Domínguez J, Galí N, Matas L, Pedroso P, Hernández A, Padilla E, et al. Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples. Eur J Clin Microbiol Infect Dis. 1999;18:896-8.
82. Romero PV, Rodríguez B, Martínez S, Cañizares R, Sepúlveda D, Manresa F. Estrés oxidativo en el condensado exhalado de pacientes con infección pulmonar grave. Arch Bronconeumol. 2006; 42: 113-9.